Codon

APRIL 30, 2023

Also, last week’s digest had an error: The country that approved the malaria vaccine was Ghana. Vaccines (basically little fat bubbles filled with mRNA and some dissolvable polymers) were physically printed onto microneedle patches using a robot. The patches have little spikes that help push the vaccines through the skin.

Vaccine 52

Vaccine DNA Engineering RNA 52

The Pharma Data

OCTOBER 14, 2020

Study May Lead to Biomarkers for Tailoring COVID-19 Vaccines and Therapeutics. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., About TNX-1800. 1 Noyce RS, et al.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40

Codon

DECEMBER 12, 2024

A mirrored organism would use right-handed molecules everywhere a naturally-occurring organism uses left-handed ones, and vice versa. Some scientists even think it had a virus defense system; “researchers say LUCA likely housed 19 CRISPR genes, which bacteria use to slice up viral threats,” reports Quanta Magazine.

DNA 104

DNA RNA Vaccine Virus 104

The Pharma Data

SEPTEMBER 9, 2020

The BNT162b2 vaccination also cleared the nose of detectable viral RNA in 100% of the SARS-CoV-2 challenged rhesus macaques within 3 days after the infection. Senior Vice President and Head of Vaccine Research & Development, Pfizer. “We Jansen, Ph.D., CEO and Co-founder of BioNTech. CEO and Co-founder of BioNTech.

Vaccine 52

Vaccine Clinical Trials RNA Trials 52

Codon

AUGUST 27, 2024

While reading all the sequences present in a sample, researchers want to find any that are out of place, such as those that belong to a never-before-seen virus. New Yorkers wait to receive a monkeypox vaccine. This cleaning, annotation, and characterization work is all performed computationally.

DNA 96

DNA Laboratories Hospitals Virus 96

The Pharma Data

AUGUST 20, 2020

times the GMT of a panel of 38 sera of SARS-CoV-2 convalescent patients, and in older adults (65-85 years of age) the vaccine candidate elicited a neutralizing GMT 1.6 study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation. Jansen, Ph.D.,

Vaccine 52

Vaccine Clinical Trials Trials Immune Response 52

Vial

DECEMBER 11, 2023

Hepatitis C virus (HCV) infection is a global health problem with complications that place a significant economic burden on national health systems. The Food and Drug Administration (FDA) approved and recommended dozens of small-molecule drugs. Genetic diversity of HCV is also a significant challenge in HGC vaccine development.

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

NIH Director's Blog: Drug Development

MAY 21, 2020

B38 blocks SARS-CoV-2 from binding to the ACE2 receptor (light pink) of a human cell, ACE2 is what the virus uses to infect cells. One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules.

Virus 52

Virus Vaccine Laboratories Small Molecule 52

The Pharma Data

OCTOBER 25, 2020

Army Medical Research and Development (USAMRDC ) initiated a Phase I clinical trial of its novel vaccine against COVID-19. The vaccine candidate is called “spike ferritin nanoparticle” (SpFN) and uses ferritin—“attaching a certain type of spike protein to a polymerized version of ferritin,” according to the organization.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

The Pharma Data

AUGUST 18, 2020

CARE will focus on three strategic pillars to achieve therapeutic breakthroughs against SARS-CoV-2 (the virus that causes COVID-19 disease) and other coronavirus threats: Drug repositioning and repurposing. Small molecule discovery. Virus-neutralizing antibody discovery.

Treatment 52

Treatment Pharmaceutical Companies Research Small Molecule 52

The Pharma Data

JANUARY 13, 2021

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. The CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions.

Pharmaceuticals 52

Pharmaceuticals Small Molecule Vaccine Protein Expression 52

The Pharma Data

JANUARY 6, 2021

. “We are leveraging our strengths in process development and manufacturing for a wide range of biopharmaceuticals such as antibodies, recombinant proteins, gene therapies and vaccines,” said Martin Meeson , chief executive officer at FUJIFILM Diosynth Biotechnologies. Overview of New Site. 1.

Packaging 52

Packaging Small Molecule Production FDA Approval 52

The Pharma Data

DECEMBER 20, 2020

CureVac announced it has enrolled the first volunteer in the pivotal Phase IIb/III trial of its own mRNA vaccine candidate, CVnCoV against COVID-19. The technology used for the CureVac vaccine is similar to that utilized by Pfizer-BioNTech and Moderna. Russia’s Sputnik V COVID-19 vaccine demonstrated 91.4%

Vaccine 52

Vaccine Trials Therapies Small Molecule 52

Drug Target Review

JULY 11, 2023

Unless two people have had a COVID vaccination in the same week, it is extremely improbable that they would have the same antibody circling. B-cell white blood cell, type of lymphocyte produce antibody molecules. She also co-founded and sits on the Board of Directors of Sevenless Therapeutics, a small molecule pain company.

Disease 75

Disease RNA Small Molecule Clinical Development 75

The Pharma Data

SEPTEMBER 15, 2020

Major revenue contributions through 2025 anticipated from Oncology, Vaccines, Rare Disease and Inflammation and Immunology. New stability, immunogenicity, and tolerability data for COVID-19 vaccine candidate, BNT162b2, presented. BNT162 mRNA-based Vaccine Program.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52

Codon

MAY 30, 2023

Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. Read A non-transmissible live attenuated SARS-CoV-2 vaccine. Read Programming inactive RNA-binding small molecules into bioactive degraders.

DNA 52

DNA RNA Engineering Vaccine 52

Codon

MAY 30, 2023

Read *An engineered influenza virus to deliver antigens for lung cancer vaccination. Read Meningococcal ACWYX conjugate vaccine in 2-to-29-year-olds in Mali and Gambia. Read A non-transmissible live attenuated SARS-CoV-2 vaccine. Read Programming inactive RNA-binding small molecules into bioactive degraders.

DNA 52

DNA RNA Engineering Vaccine 52

The Pharma Data

JANUARY 18, 2021

Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T”), antibody-drug conjugates (“ADC”), and clinical stage oncolytic virus (“Seprehvir ® ”).

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

Codon

APRIL 2, 2023

mRNA vaccines and hybrid immunity use different B cell germlines against Omicron BA.4 Read How well do different antibodies, created by people who got two or three doses of the COVID-19 mRNA vaccine, fight off new viral variants, such as BA.4 Read Small-molecule aptamer for regulating RNA functions in mammalian cells and animals.

DNA 52

DNA RNA Engineering Licensing 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. Polio/Pertussis/Hib vaccines (incl. Influenza vaccines (incl. Meningitis/Pneumo vaccines (incl.

Vaccine 52

Vaccine Production FDA Disease 52

Agency IQ

NOVEMBER 3, 2023

Synthetic biotics have been engineered to perform a variety of functions: “ Several classes of effectors have been engineered into bacteria, including enzyme pathways that metabolize disease-causing toxins, production of protein effectors, and production of small-molecule effectors,” according to a recent article on the topic.

Therapies 40

Therapies Science FDA Production 40

The Pharma Data

MARCH 11, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced real-world evidence demonstrating dramatically lower incidence rates of COVID-19 disease in individuals fully vaccinated with the Pfizer-BioNTech COVID-19 Vaccine (BNT162b2), underscoring the observed substantial public health impact of Israel’s nationwide immunization program.

Vaccine 52

Vaccine Clinical Trials Hospitals Licensing 52

The Pharma Data

JULY 21, 2021

(NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the signing of a letter of intent with The Biovac Institute (Pty) Ltd, known as “Biovac,” a Cape Town-based, South African biopharmaceutical company, to manufacture the Pfizer-BioNTech COVID-19 Vaccine for distribution within the African Union. This press release features multimedia.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 6, 2021

Under the MoU, the companies and the IOC will coordinate with National Olympic Committees (NOCs) around the world to understand and work to help address the local need for vaccine doses for national delegations’ participation in the Games. We are proud to play a role in providing vaccines to athletes and national Olympic delegations.”.

Vaccine 52

Vaccine Clinical Trials Licensing Licensing 52

The Pharma Data

MAY 7, 2021

The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S. Since then, the companies have delivered more than 170 million doses of the vaccine across the U.S. We are proud of the tremendous progress we’ve made since December in delivering vaccines to millions of Americans, in collaboration with the U.S.

Licensing 52

Licensing Licensing Vaccine FDA Approval 52

Drug Target Review

FEBRUARY 15, 2024

Since the 20 th century, all known viral pandemics, including HIV, influenza, SARS CoV-1, SARS, CoV-1, and mpox, have resulted from a virus ‘spilling over’ from animals into humans. One of the most effective ways to protect humans from novel pathogens is through vaccines, therapeutics, and other medical countermeasures.

Drug Development 122

Drug Development Virus Vaccine Government 122

The Pharma Data

DECEMBER 10, 2020

. Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose. Jansen, Ph.D.,

Vaccine 52

Vaccine Trials Clinical Trials Therapies 52

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About Pfizer: Breakthroughs That Change Patients’ Lives.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

MARCH 29, 2022

Food and Drug Administration (FDA) has expanded the emergency use of their COVID-19 vaccine to include a second booster dose in adults ages 50 years and older who have previously received a first booster of any authorized COVID-19 vaccine. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S.

Vaccine 52

Vaccine Small Molecule FDA Therapies 52

The Pharma Data

MARCH 29, 2022

Once approved, this compound could be used in combination with already available drugs that inhibit the virus’ replication, to provide a stronger defense against COVID-19 variants of concern,” says Dr. Jean, founder of FINDER, the state-of-the-art level three biocontainment facility where the work on SARS-CoV-2 variants was conducted.

Virus 52

Virus Small Molecule Research Clinical Trials 52

The Pharma Data

SEPTEMBER 8, 2020

— Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

SEPTEMBER 8, 2020

Nine CEOs sign historic pledge to continue to make the safety and well-being of vaccinated individuals the top priority in development of the first COVID-19 vaccines. FDA has established clear guidance for the development of COVID-19 vaccines and clear criteria for their potential authorization or approval in the US.

Science 52

Science Vaccine Clinical Trials Pharmaceutical Companies 52

The Pharma Data

OCTOBER 26, 2020

Demand for our products remains robust, and production, supply and distribution of our medicines, vaccines and animal health products are moving forward with minimal disruption,” said Kenneth C. The FDA has granted V181, the company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.

Vaccine 40

Vaccine Trials Treatment Therapies 40

The Pharma Data

MARCH 24, 2021

Strong R&D commitment to developing therapeutics against SARS-CoV-2 virus. Other COVID-19 initiatives include the research and development of SARS-CoV-2 antibodies that can be combined with BI 767551, small molecules to inhibit its replication, and therapy development to prevent micro coagulation (blood clots). billion EUR.

Therapies 52

Therapies Disease Vaccine Small Molecule 52

The Pharma Data

DECEMBER 27, 2020

CureVac and the University Medical Center of Mainz launched a Phase III trial of CVnCoV, their COVID-19 vaccine candidate, in healthcare workers. The study will evaluate the safety and immunogenicity of the vaccine in a two-dose schedule of 12 micrograms. platforms and the human GM-CSF cytokine.

Trials 52

Trials Clinical Trials Therapies RNA 52

The Pharma Data

APRIL 7, 2021

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Viral reactivation including herpes virus and hepatitis B reactivation have been reported. VACCINATIONS. Avoid use of live vaccines concurrently with XELJANZ. About Abrocitinib. MALIGNANCIES.

Treatment 52

Treatment Clinical Trials Therapies Vaccine 52

The Pharma Data

JULY 21, 2021

Abrocitinib is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Viral reactivation including herpes virus and hepatitis B reactivation have been reported. VACCINATIONS. Avoid use of live vaccines concurrently with XELJANZ. About Abrocitinib. MALIGNANCIES.

FDA 52

FDA Clinical Trials Treatment Therapies 52